June 28th Solensia first dose

Not a good morning for FluffyBum
We began by asking our vet to give her a dose of Gabapentin so we could watch a professional administer a tablet, That didn't go down too well, she hates tablets.
Then it was time to give her the fist injection of Solensia.
A large and very cold (refrigerated) dose.
One needle went flying as she fought back and the vet ended up having to give the dose in three different places.
We are hoping for a good result with this monthly injection.

SOLENSIA® is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in cats
SOLENSIA® works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, LIBRELA®, was received in November 2020
ZAVENTEM, BELGIUM, February 17, 2021 – Zoetis today announced that the European Commission has granted the marketing authorization for SOLENSIA® (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition1, existing in 40% of cats, and may generate pain and limit a cat’s comfort and quality of life if not treated.

SOLENSIA® works differently from current treatment options, by targeting Nerve Growth Factor (NGF), a key player in osteoarthritis (OA) pain.1,2 It functions like naturally occurring antibodies, with minimal involvement of the liver or kidneys in their metabolism and elimination process, and minimal gastrointestinal impact.3 It is delivered by the veterinarian as a monthly injection (under the skin).


By alleviating pain, SOLENSIA® helps generally improve physical activity level, sociability and quality of life of cats with OA. This new product’s benefits are effective pain relief, combined with a positive safety profile in a monthly injectable treatment for OA pain in cats. In a clinical study over three months, pet owners observed signs of pain, including physical activity level, sociability, and quality of life. A total of 76% of cat owners reported sustained improvement in signs of pain when their cats were treated with SOLENSIA®.


Margaret E. Gruen4, DVM, MVPH, PhD, DACVB, Assistant Professor of Behavioral Medicine at North Carolina State University, said: “My clinical research, and personal experience, has shown that OA pain can affect cats in a variety of ways. It impairs their ability to perform their activities of daily living and negatively impacts their quality of life. OA pain can also affect sleep, cognitive function, affect (emotion) and social relationships.”


“NGF is one of the key factors mediating pain, inducing the release of both pro-inflammatory mediators and more NGF contributing to a cycle of pain and inflammation. Anti-NGF therapy could be the most exciting therapeutic advancement in more than 20 years in veterinary medicine to control OA pain, and I welcome this innovative tool for clinicians working to alleviate OA pain. The monthly administration makes it especially useful for cats, with the potential to bring pain relief to millions of cats who suffer from OA,” she said.


Veterinarians believe that SOLENSIA would help more cats with OA pain be treated and for longer5.



.